ERS Genomics and Sai Life Sciences Sign CRISPR/Cas9 License Agreement to Advance Precision Genome Editing in Drug Discovery and Development

Summary

ERS Genomics and Sai Life Sciences entered into a CRISPR/Cas9 license agreement to advance precision genome editing in drug discovery and development. The agreement grants Sai Life Sciences access to foundational CRISPR/Cas9 intellectual property to strengthen its discovery and development platforms.